|Daily Range||$34.02 - $34.34|
|52-Week Range||$32.08 - $38.54|
|Dividend (Yield)||$0.00 (2.4%)|
|Average Daily Volume||891,047|
|Current FY EPS||$1.85|
News & Commentary
GlaxoSmithKline and PDL BioPharma offer investors sector-crushing yields at current levels. But there's good reason to believe they won't last much longer.
Pfizer is among several potential bidders rumored to be in talks with the London-based pharmaceutical giant regarding a possible takeover.
Companies are working hard to tailor healthcare to individuals. Find out which stocks have been most successful.
Exelixis Inc.'s FDA review for approval of cobimetinib has been delayed until November.
A detailed step-by-step guide on how a drug goes from a concept in the lab to a product on pharmacy shelves, and how the drug development process can affect your investments.
The biotech sector has already had an incredible run, but these two stocks look as if their momentum could continue for years to come.
Cancer immunotherapy is rapidly becoming a major new weapon in the fight against this deadly disease. Here is a brief primer on this powerful new technology, as well as a look at where it's likely headed moving forward.
Nearly 90% of biotech stocks are losing money, but that doesn't mean our healthcare analysts don't perceive there to be value in the sector.
A closer look at gene sequencing stocks -- and how you could score a double helix of gains
Could Roche, iRobot, and IBM represent the future of healthcare?